vs
Side-by-side financial comparison of Elanco Animal Health Inc (ELAN) and Lineage, Inc. (LINE). Click either name above to swap in a different company.
Lineage, Inc. is the larger business by last-quarter revenue ($1.3B vs $1.1B, roughly 1.1× Elanco Animal Health Inc). Lineage, Inc. runs the higher net margin — -3.9% vs -24.1%, a 20.2% gap on every dollar of revenue. On growth, Elanco Animal Health Inc posted the faster year-over-year revenue change (12.2% vs 0.4%). Over the past eight quarters, Lineage, Inc.'s revenue compounded faster (-1.2% CAGR vs -2.6%).
Elanco Animal Health Incorporated is an American pharmaceutical company which produces medicines and vaccinations for pets and livestock. Until 2019, the company was a subsidiary of Eli Lilly and Company, before being divested. It is the third-largest animal health company in the world.
Norwegian Cruise Line Holdings (NCLH) is a holding company that is based in the United States and domiciled in Bermuda. It operates three cruise lines as wholly owned subsidiaries: Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises. With its subsidiaries combined, it is the third-largest cruise operator in the world. It is a publicly traded company listed on the New York Stock Exchange.
ELAN vs LINE — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.1B | $1.3B |
| Net Profit | $-276.0M | $-51.0M |
| Gross Margin | 51.5% | — |
| Operating Margin | -22.6% | 2.8% |
| Net Margin | -24.1% | -3.9% |
| Revenue YoY | 12.2% | 0.4% |
| Net Profit YoY | -3350.0% | — |
| EPS (diluted) | $-0.55 | $-0.18 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $1.3B | ||
| Q4 25 | $1.1B | — | ||
| Q3 25 | $1.1B | $1.4B | ||
| Q2 25 | $1.2B | $1.4B | ||
| Q1 25 | $1.2B | $1.3B | ||
| Q4 24 | $1.0B | $1.3B | ||
| Q3 24 | $1.0B | $1.3B | ||
| Q2 24 | $1.2B | $1.3B |
| Q1 26 | — | $-51.0M | ||
| Q4 25 | $-276.0M | — | ||
| Q3 25 | $-34.0M | $-100.0M | ||
| Q2 25 | $11.0M | $-6.0M | ||
| Q1 25 | $67.0M | $0 | ||
| Q4 24 | $-8.0M | $-71.0M | ||
| Q3 24 | $364.0M | $-485.0M | ||
| Q2 24 | $-50.0M | $-68.0M |
| Q1 26 | — | — | ||
| Q4 25 | 51.5% | — | ||
| Q3 25 | 53.4% | 32.3% | ||
| Q2 25 | 57.5% | 31.9% | ||
| Q1 25 | 57.3% | 32.2% | ||
| Q4 24 | 50.9% | 32.3% | ||
| Q3 24 | 52.2% | 32.8% | ||
| Q2 24 | 58.2% | 33.4% |
| Q1 26 | — | 2.8% | ||
| Q4 25 | -22.6% | — | ||
| Q3 25 | -4.4% | 2.5% | ||
| Q2 25 | 2.0% | 1.7% | ||
| Q1 25 | 5.0% | 4.3% | ||
| Q4 24 | -5.0% | -1.6% | ||
| Q3 24 | 54.3% | -38.6% | ||
| Q2 24 | -2.7% | 5.5% |
| Q1 26 | — | -3.9% | ||
| Q4 25 | -24.1% | — | ||
| Q3 25 | -3.0% | -7.3% | ||
| Q2 25 | 0.9% | -0.4% | ||
| Q1 25 | 5.6% | — | ||
| Q4 24 | -0.8% | -5.3% | ||
| Q3 24 | 35.3% | -36.3% | ||
| Q2 24 | -4.2% | -5.1% |
| Q1 26 | — | $-0.18 | ||
| Q4 25 | $-0.55 | — | ||
| Q3 25 | $-0.07 | $-0.44 | ||
| Q2 25 | $0.02 | $-0.03 | ||
| Q1 25 | $0.13 | $0.01 | ||
| Q4 24 | $-0.01 | $-0.52 | ||
| Q3 24 | $0.73 | $-2.44 | ||
| Q2 24 | $-0.10 | $-0.46 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $545.0M | — |
| Total DebtLower is stronger | $3.9B | — |
| Stockholders' EquityBook value | $6.5B | $8.1B |
| Total Assets | $13.4B | $19.0B |
| Debt / EquityLower = less leverage | 0.60× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $545.0M | — | ||
| Q3 25 | $505.0M | — | ||
| Q2 25 | $539.0M | — | ||
| Q1 25 | $487.0M | — | ||
| Q4 24 | $468.0M | $173.0M | ||
| Q3 24 | $490.0M | $409.0M | ||
| Q2 24 | $416.0M | $73.0M |
| Q1 26 | — | — | ||
| Q4 25 | $3.9B | — | ||
| Q3 25 | $4.0B | — | ||
| Q2 25 | $4.1B | — | ||
| Q1 25 | $4.4B | — | ||
| Q4 24 | $4.3B | — | ||
| Q3 24 | $4.4B | — | ||
| Q2 24 | $5.7B | — |
| Q1 26 | — | $8.1B | ||
| Q4 25 | $6.5B | — | ||
| Q3 25 | $6.7B | $8.4B | ||
| Q2 25 | $6.8B | $8.6B | ||
| Q1 25 | $6.4B | $8.6B | ||
| Q4 24 | $6.1B | $8.6B | ||
| Q3 24 | $6.5B | $9.0B | ||
| Q2 24 | $5.9B | $4.9B |
| Q1 26 | — | $19.0B | ||
| Q4 25 | $13.4B | — | ||
| Q3 25 | $13.6B | $19.2B | ||
| Q2 25 | $13.7B | $19.4B | ||
| Q1 25 | $12.9B | $18.8B | ||
| Q4 24 | $12.6B | $18.7B | ||
| Q3 24 | $13.3B | $19.3B | ||
| Q2 24 | $13.8B | $18.8B |
| Q1 26 | — | — | ||
| Q4 25 | 0.60× | — | ||
| Q3 25 | 0.59× | — | ||
| Q2 25 | 0.61× | — | ||
| Q1 25 | 0.69× | — | ||
| Q4 24 | 0.70× | — | ||
| Q3 24 | 0.67× | — | ||
| Q2 24 | 0.96× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $108.0M | $130.0M |
| Free Cash FlowOCF − Capex | $46.0M | — |
| FCF MarginFCF / Revenue | 4.0% | — |
| Capex IntensityCapex / Revenue | 5.4% | 2.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $284.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $130.0M | ||
| Q4 25 | $108.0M | — | ||
| Q3 25 | $219.0M | $230.0M | ||
| Q2 25 | $237.0M | $258.0M | ||
| Q1 25 | $-4.0M | $139.0M | ||
| Q4 24 | $177.0M | — | ||
| Q3 24 | $162.0M | $186.0M | ||
| Q2 24 | $200.0M | $155.0M |
| Q1 26 | — | — | ||
| Q4 25 | $46.0M | — | ||
| Q3 25 | $127.0M | $35.0M | ||
| Q2 25 | $180.0M | $95.0M | ||
| Q1 25 | $-69.0M | $-12.0M | ||
| Q4 24 | $130.0M | — | ||
| Q3 24 | $120.0M | $33.0M | ||
| Q2 24 | $166.0M | $-31.0M |
| Q1 26 | — | — | ||
| Q4 25 | 4.0% | — | ||
| Q3 25 | 11.2% | 2.5% | ||
| Q2 25 | 14.5% | 7.0% | ||
| Q1 25 | -5.8% | -0.9% | ||
| Q4 24 | 12.7% | — | ||
| Q3 24 | 11.7% | 2.5% | ||
| Q2 24 | 14.0% | -2.3% |
| Q1 26 | — | 2.4% | ||
| Q4 25 | 5.4% | — | ||
| Q3 25 | 8.1% | 14.2% | ||
| Q2 25 | 4.6% | 12.1% | ||
| Q1 25 | 5.4% | 11.7% | ||
| Q4 24 | 4.6% | — | ||
| Q3 24 | 4.1% | 11.5% | ||
| Q2 24 | 2.9% | 13.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 21.55× | — | ||
| Q1 25 | -0.06× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.45× | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ELAN
| Pet Health | $489.0M | 43% |
| Cattle | $296.0M | 26% |
| Poultry | $237.0M | 21% |
| Swine | $107.0M | 9% |
| Contract Manufacturing | $15.0M | 1% |
LINE
Segment breakdown not available.
